Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention

Ertan Okmen1, Arda Sanli, Huseyin Uyarel

  • 1Department of Cardiology, Siyami Ersek Cardiovascular and Thoracic Surgery Center, Istanbul, Turkey. ertanokmen@hotmail.com

Angiology
|May 17, 2006
PubMed

Insights

Glycoprotein IIb/IIIa inhibition did not immediately improve QT dispersion after percutaneous coronary intervention (PCI). However, it offered long-lasting benefits by reducing myocardial necrosis and improving QT dispersion recovery.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Interventional Cardiology

Background:

  • Coronary ischemia increases ventricular repolarization inhomogeneity.
  • Successful percutaneous coronary intervention (PCI) typically reduces QT dispersion (QTd).

Purpose of the Study:

  • To investigate if glycoprotein IIb/IIIa (GP IIb/IIIa) inhibition offers additional benefits on QT dispersion post-PCI.
  • To assess the impact of GP IIb/IIIa inhibition on myocardial damage and QT dispersion recovery.

Main Methods:

  • 111 patients undergoing elective PCI were randomized to standard therapy or standard therapy plus tirofiban.
  • 12-lead ECGs were recorded pre-PCI and at 6, 12, and 24 hours post-PCI to measure QTd and corrected QTd (QTcd).
  • Blood samples were collected to assess postprocedural myocardial damage (CK-MB, cTn-I).

Main Results:

  • QTd and QTcd were not significantly different between groups immediately post-PCI or at 6 hours.
  • At 24 hours post-PCI, QTd and QTcd were significantly longer in the standard therapy group compared to the tirofiban group (p=0.047 and p=0.001, respectively).
  • Tirofiban use was associated with reduced postprocedural troponin-I elevation and predicted better long-term QT dispersion recovery.

Conclusions:

  • GP IIb/IIIa inhibition did not provide early advantages in QT dispersion recovery after successful PCI.
  • GP IIb/IIIa inhibition demonstrated a trend towards preventing minor myocardial necrosis.
  • GP IIb/IIIa inhibition facilitated a more sustained recovery of QT dispersion up to 24 hours post-PCI.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...